CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
双特异性 T 细胞衔接器在滤泡性和大 B 细胞淋巴瘤治疗中的出现
英文原题：The emergence of bispecific T-cell engagers in the treatment of follicular and large B-cell lymphomas.
查看英文原题
The emergence of bispecific T-cell engagers in the treatment of follicular and large B-cell lymphomas.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CD20靶向T细胞衔接器在滤泡性淋巴瘤和大B细胞淋巴瘤中的迅速出现，进一步扩大了复发/难治性疾病患者的治疗选择。本文中，我们回顾并讨论了mosunetuzumab、epcoritamab和glofitamab的标准治疗产品及适应证。我们详细概述了注册性临床试验，并回顾了正在进行的试验和可能的未来适应证。我们还讨论了如何将T细胞衔接器纳入我们当前的治疗范式，特别强调其与CAR-T 细胞疗法的联合使用以及作为其替代方案的应用。我们进一步讨论了免疫效应细胞相关毒性的管理。
展开英文摘要原文
The rapid emergence of CD20-targeting T-cell engagers in follicular lymphoma and large B-cell lymphoma has further expanded the treatment options for patients with relapsed or refractory disease.
Herein, we review and discuss the standard-of-care products and indications for mosunetuzumab, epcoritamab, and glofitamab.
We provide a detailed overview of the registrational clinical trials, as well as a review of ongoing trials and likely future indications.
We also address how we incorporate T-cell engagers in our current treatment paradigm, with particular emphasis on their use with and as alternatives to chimeric antigen receptor T-cell therapy.
We further discuss our management of immune effector cell-related toxicities.
论文信息
- 作者
- Lutfi FG、Ahmed N、Hoffmann MS、Tun A、McGuirk JP
- 单位
- Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas.United States
- 文献类型
- 综述
- 期刊
- Clinical advances in hematology & oncology : H&O2024 Dec
- 原文标识
- PubMed 39820375